Cascade Financial Partners’s Protalix BioTherapeutics PLX Stock Holding History

Cascade Financial Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28K	Hold	12,000	–	–	﹤0.01%	279
2026 Q1	$26K	Hold	12,000	–	–	﹤0.01%	262
2025 Q4	$21.6K	Sell	12,000 -5,000	-29%	-$10.2K	﹤0.01%	271
2025 Q3	$37.7K	Hold	17,000	–	–	﹤0.01%	261
2025 Q2	$25.2K	Buy	+17,000	New	+$34.8K	﹤0.01%	259
2024 Q3	–	Sell	-11,100	Closed	-$13K	–	242
2024 Q2	$13K	Buy	+11,100	New	+$13.1K	﹤0.01%	233

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cascade Financial Partners's PLX Position: Q2 2026 in Review

Cascade Financial Partners held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 12,000 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #279.

Cascade Financial Partners first reported a position in PLX in Q2 2024 and has held it in 6 quarters since. The position peaked at $37.7K in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Cascade Financial Partners held 12,000 shares of Protalix BioTherapeutics worth $28K as of Q2 2026.
Cascade Financial Partners left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Cascade Financial Partners's portfolio in Q2 2026, its #279 holding.
Cascade Financial Partners first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 6 quarters since.
Cascade Financial Partners's Protalix BioTherapeutics position peaked at $37.7K in Q3 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Cascade Financial Partners's 13F filing for Q2 2026, filed 4 Aug 2026.